GlassScriptPhysician profile
Maya Estephan
NPI 1851687313
$12,143.11
in general payments reported to CMS, 2019-2025
37 companies · $3,066 in 2025
The $3,066 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $498 · 2021: $1,422 · 2022: $1,831 · 2023: $1,378 · 2024: $2,542 · 2025: $3,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,890 · Education: $94.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,890.23 |
| Education | $94.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,373.94 | 2019-2025 | Evenity, Enbrel, Tavneos |
| Abbvie INC. | $2,207.09 | 2019-2025 | |
| Pfizer INC. | $1,283.64 | 2019-2025 | |
| Janssen Biotech, INC. | $1,009.44 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $680.18 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $482.83 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $472.47 | 2021-2025 | Saphnelo |
| Ucb, INC. | $441.27 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $413.76 | 2019-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $311.28 | 2022-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $298.87 | 2019-2024 | Taltz |
| Genentech USA, INC. | $278.98 | 2019-2025 | Actemra |
| Alexion Pharmaceuticals, INC. | $265.31 | 2021-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $214.03 | 2021-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $178.84 | 2019-2025 | Orencia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $122.84 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $120.60 | 2023-2025 | Tyenne |
| Organon LLC | $109.91 | 2022-2025 | Renflexis, Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $107.65 | 2023-2025 | Hyqvia, Takhzyro |
| Horizon Therapeutics Plc | $104.57 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $88.44 | 2024-2025 | |
| Radius Health, INC. | $86.41 | 2019-2024 | Tymlos |
| Hospira, INC. | $62.31 | 2024-2025 | |
| Tersera Therapeutics LLC | $50.83 | 2024-2025 | Quzyttir |
| Regeneron Healthcare Solutions, INC. | $48.89 | 2019 | |
| Genentech, INC. | $47.95 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $44.50 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.14 | 2024-2025 | Ofev |
| Grifols USA, LLC | $27.74 | 2025 | Gamunex-C |
| Invivyd INC | $26.46 | 2025 | Pemgarda |
| Zyla Life Sciences, INC. | $25.68 | 2019 | |
| Biocon Biologics INC | $24.50 | 2023 | Hulio |
| Ultragenyx Pharmaceutical INC. | $22.42 | 2022 | |
| Mallinckrodt Enterprises LLC | $21.52 | 2019 | |
| Gilead Sciences, INC. | $20.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.07 | 2024 | Truxima |
| Celgene Corporation | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Estephan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.